| Aug 16 |
Ocuphire Pharma, Inc. (NASDAQ:OCUP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
|
| Aug 13 |
Ocuphire Pharma GAAP EPS of -$0.30, revenue of $1.11M
|
| Aug 13 |
Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update
|
| Aug 8 |
Ocuphire Pharma to Present at Two Investor Conferences in August
|
| Aug 1 |
Here's Why We're Not At All Concerned With Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation
|
| Jul 10 |
Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July
|
| Jun 6 |
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
|
| May 22 |
Duos Technologies And 2 Other Stocks Under $3 Insiders Are Buying
|
